Viduet is in the semifinals of the European EIT Health Catapult program!

We proudly announce that we are selected for the semifinals of the EIT Health Catapult program! Each year, the competition showcases Europe’s most promising biotech, medtech and digital health scale-ups to leading experts and investors. A total of 42 promising scale-ups were selected. During the semifinals, we competed against 14 companies excelling in the category: Digital Health. On December 1, we gave our pitch. We are still waiting for the results of this semifinal. The finalists will be announced on January 23, 2023!

EIT Health Catapult
Is a unique competition and training program that brings scale-ups to the attention of leading experts and investors across Europe. The program recognizes and rewards the very best business concepts, fast scale-ups to become part of the EIT Health Community of leading companies. This rewarding competition spotlights scale-ups with the most value for users and customers. Throughout the process, participants receive intensive training.

Selection and training
With us, a total of 42 promising scale-ups had been selected. Each of the 42 scale-ups nominated , went through an extensive preselection process. After this, we have the opportunity to receive high-quality, individualized training to prepare for the semifinals. Part of the training included a pitch training in Paris.

During the semifinals on Dec. 1, 2022, we had to compete against 14 companies in the category: Digital Health. We presented our digital solution to an audience of healthcare professionals, industry experts, investors and more. The winners of the semifinals will receive prizes from sponsors including Amazon Web Services (AWS), Astrazeneca, e.g. Technology, Lusíadas Saúde, McDermott Will and Emery, and Merck.

The three best scale-ups from each of the categories will be selected and invited to pitch during the finals at a major healthcare event. These 3 best in each category will compete against each other for their share of the €210,000 prize money. The winner of the public award will be displayed at the New York Nasdaq Tower.

The results of the semifinals are still unknown. The finalists will be announced on January 23, 2023!

Catapult success stories
Many of our predecessors in the Catapult program have become successful. For example, Catapult 2019 winner Sparing Vision has raised €44.5 million to develop their breakthrough treatment to accelerate the management of chronic eye disease by 2020. Over the past two years, Sparing Vision has had positive preclinical findings and plans to submit their clinical trial application (CTA) in Q3 2022. To read more go to

ISO 27001NEN 7510CE